Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)

Temodal (TMZ) in Concomitant Radiochemotherapy Followed by Sequential TMZ Chemotherapy in Newly Diagnosed Glioblastoma Multiforme Patients - an Observational Program

The purpose of this program is to evaluate the safety, tolerability, and efficacy of the new concomitant and sequential temozolomide regimen in newly diagnosed Glioblastoma patients in a routine care setting.

Participant sampling method: consecutive patient sampling.

Inclusion Criteria:

• Newly diagnosed Glioblastoma multiforme

Exclusion Criteria:

• History of hypersensitivity to temozolomide or its components, or to dacarbazine.
• Women who are pregnant or breast-feeding.
• Patients with severe myelosuppression.